Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
Justus M. Huelse, Diana Fridlyand, Shelton Earp, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107577-107577
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Drugging the efferocytosis process: concepts and opportunities
Parul Mehrotra, Kodi S. Ravichandran
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 8, pp. 601-620
Open Access | Times Cited: 204
Tumor-associated macrophages: an effective player of the tumor microenvironment
Udit Basak, Tania Sarkar, Sumon Mukherjee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 94
Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity
Wanru Zhuang, Yunfeng Wang, Weidong Nie, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 57
Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma
Shun Wang, Zhu Le, Tianen Li, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101415-101415
Open Access | Times Cited: 27
AXL signaling in cancer: from molecular insights to targeted therapies
Monika Yadav, Anuj K. Sharma, Ketki Patne, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention
Xuefei Zhou, Xiangrui Liu, Leaf Huang
Advanced Functional Materials (2020) Vol. 31, Iss. 5
Open Access | Times Cited: 114
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression
Jinti Lin, Ankai Xu, Jiakang Jin, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 57
Comprehensive proteogenomic characterization of rare kidney tumors
Ginny Xiaohe Li, Lijun Chen, Yi Hsiao, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101547-101547
Open Access | Times Cited: 13
TAM Receptor Inhibition–Implications for Cancer and the Immune System
Pia Aehnlich, Richard Powell, Marlies J. W. Peeters, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1195-1195
Open Access | Times Cited: 55
Tissue-specific modifier alleles determine Mertk loss-of-function traits
Yemsratch T. Akalu, María E. Mercau, Marleen Ansems, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 35
Protocatechuic acid boosts continual efferocytosis in macrophages by derepressing KLF4 to transcriptionally activate MerTK
Qing Li, Xiuping Liu, Yushi Du, et al.
Science Signaling (2023) Vol. 16, Iss. 786
Closed Access | Times Cited: 17
Big data analytics for MerTK genomics reveals its double-edged sword functions in human diseases
Shijie Liu, Jinzi Wu, Daixuan Yang, et al.
Redox Biology (2024) Vol. 70, pp. 103061-103061
Open Access | Times Cited: 8
Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression
Vincenzo Quagliariello, Massimiliano Berretta, Simona Buccolo, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 38
Mertk: An emerging target in cancer biology and immuno-oncology
Kevin C. Lahey, Varsha Gadiyar, Amanda A. Hill, et al.
International review of cell and molecular biology (2022), pp. 35-59
Open Access | Times Cited: 22
Distinct TYRO3 and PROS1 expression levels contribute to preeclampsia pathogenesis
Esma Konuk, Ertan Katırcı, Mehmet Şimşek
Histochemistry and Cell Biology (2025) Vol. 163, Iss. 1
Closed Access
Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment
Guoqiang Zhu, Xinliang Wan, Wanyin Wu, et al.
Small Science (2025)
Open Access
Navigating TAM receptor dynamics in tumour immunotherapy
Jihao Yang, Guanmin Chen, Rui Wang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 5
Open Access
Recent advances in TAM mechanisms in lung diseases
Jia-Qi Ban, Jiayi Qian, Chi Zhang, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma
Naita M. Wirsik, Mingyi Chen, Liping He, et al.
Cancer Medicine (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 3
Regulation of Mertk Surface Expression via ADAM17 and γ-Secretase Proteolytic Processing
Kevin C. Lahey, Christopher Varsanyi, Ziren Wang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4404-4404
Open Access | Times Cited: 3
MERTK inhibition selectively activates a DC – T-cell axis to provide anti-leukemia immunity
Justus M. Huelse, Swati S. Bhasin, Kristen M. Jacobsen, et al.
Leukemia (2024) Vol. 38, Iss. 12, pp. 2685-2698
Closed Access | Times Cited: 3
The role of macrophage TAM receptor family in the acute‐to‐chronic progression of liver disease: From friend to foe?
Haitao Huang, Jingyu Jiang, Ruihan Chen, et al.
Liver International (2022) Vol. 42, Iss. 12, pp. 2620-2631
Closed Access | Times Cited: 16
A novel GSH-activable theranostic probe containing kinase inhibitor for synergistic treatment and selective imaging of tumor cells
Caiyun Liu, Yan Zhang, Weimin Sun, et al.
Talanta (2023) Vol. 260, pp. 124567-124567
Closed Access | Times Cited: 9
Leveraging efferocytosis blockade for improved cancer chemo-immunotherapy through synchronized release of doxorubicin and BMS777607 confined within tailored mesoporous silica nanoparticles
Jingyang Zhang, Fangman Chen, Yuxuan Li, et al.
Nano Today (2023) Vol. 53, pp. 102039-102039
Closed Access | Times Cited: 9
Resistance mechanisms to checkpoint inhibitors
Sarah A. Weiss, Mario Sznol
Current Opinion in Immunology (2021) Vol. 69, pp. 47-55
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top